11 minute read
Apr. 24, 2023

A Potential Next Best-In-Class Allosteric TYK2 Inhibitor Exhibits Strong Ph. II Results for Plaque Psoriasis

TAK-279 (NDI-034858)

oral, once-daily, allosteric TYK2 inhibitor Ph. IIb for moderate-to-severe plaque psoriasis FEP+ supported VLS + core hopping w/ TYK2-JH2 Xtal structure Press release, March 18, 2023 Nimbus Therapeutics, MA / Takeda, JP

drughunter.com
Drug Hunter Team

Takeda Pharmaceuticals has announced positive results for TAK-279 in Ph. IIb for the treatment of moderate-to-severe plaque psoriasis (PsO). Just disclosed last year , TAK-279 (formerly known as NDI-034858) was acquired by Takeda from [...]

Loading...

twitterlinkedinemail

Other molecules you may be interested in